Donepezil

Donepezil is a centrally acting, reversible inhibitor of the enzyme acetylcholinesterase, placing it in the class of drugs known as cholinesterase inhibitors ^[2]. It was developed by the pharmaceutical company Eisai, with a research team led by Hachiro Sugimoto, and was approved in the United States in 1996 ^[2]. It is marketed under the brand name Aricept and is now available as an inexpensive generic medicine ^[1].

The drug is used to treat the cognitive and functional symptoms of dementia caused by Alzheimer's disease, and it is approved for mild, moderate, and severe stages of the illness ^[1]. It has also been used, sometimes outside its formal approvals, in other forms of dementia, including dementia associated with Parkinson's disease, vascular dementia, and dementia with Lewy bodies ^[2]. Donepezil is a symptomatic treatment: it can improve or stabilize symptoms for a time but does not change the course of the underlying degenerative process ^[1].

Systematic reviews of controlled trials have concluded that donepezil produces small but measurable benefits in thinking, everyday function, and overall clinical impression in people with Alzheimer's dementia, generally over treatment periods of a few months ^[1]. A large, long-term British trial known as AD2000 similarly reported cognitive and functional benefits but did not find significant effects on major outcomes such as the need for institutional care or the progression of disability ^[3]. Because the benefits are modest and not universal, guidelines suggest reviewing treatment and stopping it if no worthwhile effect is seen ^[1].

Donepezil is taken once daily, usually as an oral tablet, including a form that dissolves in the mouth, and it is also available as a skin patch ^[1][2]. It is a prescription-only medicine and appears on the World Health Organization's list of essential medicines. Its side effects arise mainly from its cholinergic action and are usually mild and temporary, most often nausea, diarrhea, loss of appetite, difficulty sleeping, and muscle cramps; less commonly it can slow the heart rate, so caution is advised in people with certain heart-rhythm conditions ^[1][2].

The common side effects are cholinergic: nausea, diarrhea, stomach cramps, appetite loss, vivid dreams or insomnia (take it earlier if the dreams get disruptive), muscle cramps and a slowed heart rate. Because it slows the heart it can cause fainting or trouble in people with certain rhythm problems, and it can aggravate asthma or COPD, ulcers, and urinary obstruction. Rare but serious issues include heart block, seizures and GI bleeding. Do not casually stack it with other acetylcholinesterase inhibitors like huperzine A, since the cholinergic effects add right up, and a big overdose causes a cholinergic crisis.

Donepezil raises synaptic acetylcholine, so its sharpest interactions are with drugs pulling the other way. Anticholinergics such as oxybutynin, benztropine, sedating antihistamines and tricyclics blunt its cognitive effect while it blunts theirs; the pairing is common in older patients and quietly cancels both.

The cardiac issue is vagotonic. Donepezil slows sinus and AV node conduction, and case series document bradyarrhythmia and syncope after it is started, in some patients leading to pacemaker implantation. Beta blockers, digoxin, verapamil and diltiazem add to that and can produce heart block. Under anesthesia, cholinesterase inhibition prolongs the action of succinylcholine.

Metabolism runs through CYP3A4 and CYP2D6, so ketoconazole, paroxetine and quinidine raise donepezil exposure, while rifampin, carbamazepine and phenytoin lower it. Cholinergic drive also increases gastric acid secretion, which compounds the ulcer and bleeding risk of NSAIDs.

Checking a whole stack? Run it through interactions + stacks.

Donepezil was discovered by the Japanese pharmaceutical company Eisai, where a research team led by the chemist Hachiro Sugimoto set out in the 1980s to design a well-tolerated, long-acting inhibitor of acetylcholinesterase for Alzheimer's disease. The molecule that emerged, then known as E2020, was selected from a large series of piperidine-based compounds for its potency and favorable pharmacokinetics.

It received United States approval in 1996 under the brand name Aricept, becoming the second cholinesterase inhibitor cleared for Alzheimer's after tacrine but offering once-daily dosing and a substantially better safety profile. Over the following years its use expanded from mild-to-moderate to severe Alzheimer's dementia, a higher 23 mg formulation was introduced, and a once-weekly transdermal patch was later approved. Donepezil has since become one of the most widely prescribed treatments for Alzheimer's dementia worldwide and a standard comparator in dementia research.

Donepezil holds an established place in dementia care as a dependable, well-studied first-line option whose benefits, while modest, are real and reproducible. Cochrane and other systematic reviews consistently find small but measurable improvements in cognition, global clinical impression, and daily function across mild, moderate, and severe stages of Alzheimer's disease. Clinicians value its simple once-daily dosing, decades of accumulated safety experience, and low cost as a generic. It is honest to emphasize that donepezil treats symptoms rather than the underlying disease; it neither halts nor reverses neurodegeneration, and its gastrointestinal and cholinergic side effects lead some patients to discontinue. Even so, for many families it provides a worthwhile period of stabilized function, which explains its enduring status as a benchmark therapy.